GalNAc-siRNA偶联药物市场按适应症、年龄层、应用类型、最终用户和分销管道划分，全球预测，2026-2032年

GalNAc-siRNA偶联药物市场预计到2025年将达到11亿美元，到2026年将成长到11.9亿美元，到2032年将达到18.2亿美元，年复合成长率为7.45%。

关键市场统计数据
基准年 2025	11亿美元
预计年份：2026年	11.9亿美元
预测年份 2032	18.2亿美元
复合年增长率 (%)	7.45%

GalNAc-siRNA偶联物的策略应用：科学原理、转化研究进展及其对治疗开发的基础意义

GalNAc连接的siRNA疗法代表了标靶基因静默药物发展的关键转折点，它结合了受体介导的肝臟递送和高效的序列特异性基因敲低。化学、递送技术和改进的双链设计之间的融合，使RNA干扰从实验室现象转变为以肝臟疾病为中心的实用治疗方法。随着学术发现逐渐转化为临床阶段的药物，药物发现、临床开发、生产和商业化领域的相关人员也调整了自身能力，以满足寡核苷酸疗法的独特需求。

技术、监管先例和商业策略的关键变革性转变将重新定义 GalNAc-siRNA 的开发和应用格局。

在科学技术的进步、监管标准的规范化以及商业模式的不断发展的推动下，GalNAc-siRNA疗法领域经历了变革性的变化。配体-受体靶向化学的进步提高了肝细胞的摄取率，同时限制了全身暴露，从而降低了安全性不确定性并缩短了转化週期。同时，研发人员正致力于优化双股化学，以提高疗效的持久性并降低给药频率，从而提高患者的依从性和医保报销的接受度。

2025年美国关税调整对GalNAc-siRNA开发人员的采购、製造在地化和供应链弹性策略的影响

美国2025年宣布实施的关税和贸易措施将对GalNAc-siRNA生态系统的供应链规划、采购和生产经济性产生重大影响。虽然治疗药物和活性药物原料药通常受益于特殊的贸易分类和协商豁免，但关税表的变化将影响试剂、原材料和支持寡核苷酸合成的专用设备的到岸成本。因此，各组织需要重新评估筹资策略和供应商合同，以降低投入成本波动的影响，同时确保产品品质和合规性。

深入的细分洞察，解释了治疗适应症、临床环境、通路、患者人口统计特征和应用类型如何驱动差异化的开发和商业化策略。

细分市场分析表明，每种疾病的治疗、终端用户环境、通路、患者群体和适应症类型都对研发和商业化策略提出了独特的要求。就适应症而言，其范围涵盖代谢性疾病、肿瘤和罕见疾病，其中代谢性疾病又细分为高胆固醇症和第2型糖尿病，肿瘤疾病主要集中于肝癌，而罕见疾病则包括遗传性转甲状腺素蛋白类淀粉沉积症和A型血友病这些临床标靶决定了不同的临床试验设计、安全性监测框架和长期疗效指标，因此计画团队需要将临床前模型与特定适应症的终点指标相匹配。

深入分析美洲、欧洲、中东和非洲以及亚太地区的趋势将如何影响临床开发、生产策略和市场进入途径的关键区域洞察

区域趋势不断影响着 GalNAc-siRNA 疗法的临床试验设计、监管互动、製造地和商业化部署计画。在美洲，完善的临床试验基础设施和成熟的医保报销环境为快速招募受试者和尽早商业性提供了机会，但也带来了支付方的严格审查和对真实世界证据的高要求。同时，欧洲、中东和非洲地区 (EMEA)法规结构和市场进入途径的多样性，要求采用统一的证据包和区域定制的卫生经济模型，以最大限度地促进不同国家体系的采纳。

主要企业洞察揭示了平台差异化、策略联盟和智慧财产权策略如何塑造竞争优势和交易结构。

GalNAc-siRNA领域各公司之间的竞争与合作行为揭示了其平台差异化和务实伙伴关係的双重关注点。领先的研发公司强调稳健的递送化学、检验的肝臟标靶化和可扩展的生产工艺，而规模较小的创新者则致力于小众适应症和新型化学方法的概念验证。在整个生态系统中，合约开发和生产组织（CDMO）合作、战略许可协议以及多学科研究合作正在迅速将临床前研究成果转化为临床阶段项目。

为行业领导者提供实用建议，以透过平台开发、供应链韧性、证据生成和商业模式调整来建立可持续的竞争优势。

治疗药物研发和商业化领域的领导者应采取一系列有针对性的措施，将科学潜力转化为永续的市场地位。首先，在计画设计早期就应纳入给药平台选择和适应症优先排序，以确保试验终点、生产计画和支付方证据策略之间的无缝衔接。其次，透过多司法管辖区的合格以及与能够扩大寡核苷酸生产规模并满足监管品质要求的契约製造建立策略合作伙伴关係，确保生产和供应链的韧性。

透过透明且可重复的调查方法提供可靠的决策支持，这些方法结合了与关键相关人员的对话、二手文献的综合分析以及交叉检验的分析方法。

本研究整合了一手和二手讯息，建构了一套严谨透明的调查方法，优先考虑研究结果的可重复性和对决策的相关性。一手资讯来自对产业主管、临床研究人员、监管专业人士、生产专家和支付方的结构化访谈，并辅以匿名化的研发专案案例研究，以了解实际挑战及其应对策略。二手分析则纳入了同行评审文献、监管指南、临床试验註册资讯、生产最佳实践和专利趋势，以验证研究结果并检验主题趋势。

简洁的结论，整合了技术进步、监管现实和策略要务，以推动 GalNAc-siRNA 计画从研发走向永续商业化。

总之，GalNAc-siRNA偶联物处于引人注目的科学进展与实际商业化挑战的交汇点，递送化学的进步和监管政策的明确性正在为其带来显着的治疗效果。平台能力的成熟催生了一种新的竞争动态，其特点是专注于平台差异化、策略伙伴关係以及确保生产韧性。同时，贸易政策的变化以及监管和报销体系的区域差异等外部因素，要求企业制定适应性策略，以平衡全球目标与本地执行。

目录

第一章：序言

第二章调查方法

• 研究设计
• 研究框架
• 市场规模预测
• 数据三角测量
• 调查结果
• 调查前提
• 调查限制

第三章执行摘要

• 首席主管观点
• 市场规模和成长趋势
• 2025年市占率分析
• FPNV定位矩阵，2025
• 新的商机
• 下一代经营模式
• 产业蓝图

第四章 市场概览

• 产业生态系与价值链分析
• 波特五力分析
• PESTEL 分析
• 市场展望
• 上市策略

第五章 市场洞察

• 消费者洞察与终端用户观点
• 消费者体验基准
• 机会地图
• 分销通路分析
• 价格趋势分析
• 监理合规和标准框架
• ESG与永续性分析
• 中断和风险情景
• 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. GalNAc-siRNA偶联药物市场依适应症划分

• 代谢性疾病
  • 高胆固醇症
  • 2型糖尿病
• 肿瘤学
• 罕见疾病
  • Hatr类淀粉沉积症
  • A型血友病A

9. 依患者年龄层分類的 GalNAc-siRNA 偶联药物市场

• 成人
• 儿童

10. GalNAc-siRNA偶联药物市场（按应用领域划分）

• 预防
• 治疗

11. GalNAc-siRNA偶联药物市场（按最终用户划分）

• 家庭医疗保健
• 医院
• 研究所
• 专科诊所

12. GalNAc-siRNA偶联药物市场依分销管道划分

• 医院药房
• 网路药房
• 零售药房

13. GalNAc-siRNA偶联药物市场（按地区划分）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

14. GalNAc-siRNA偶联药物市场（依组别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

15. 各国 GalNAc-siRNA 偶联药物市场

• 我们
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

16. 美国 GalNAc-siRNA 偶联药物市场

17. 中国 GalNAc-siRNA 偶联药物市场

第十八章 竞争格局

• 市场集中度分析，2025年
  • 浓度比（CR）
  • 赫芬达尔-赫希曼指数 (HHI)
• 近期趋势及影响分析，2025 年
• 2025年产品系列分析
• 基准分析，2025 年
• Akcea Therapeutics, Inc.
• Alnylam Pharmaceuticals, Inc.
• Arrowhead Pharmaceuticals, Inc.
• AstraZeneca plc
• BioNTech SE
• CureVac NV
• Dicerna Pharmaceuticals, Inc.
• GlaxoSmithKline plc
• Ionis Pharmaceuticals, Inc.
• Moderna, Inc.
• Novartis AG
• Novo Nordisk A/S
• Pfizer Inc.
• Roche Holding AG
• Sanofi SA
• Sarepta Therapeutics, Inc.
• Takeda Pharmaceutical Company Limited

The GalNAc-siRNA Conjugates Drug Market was valued at USD 1.10 billion in 2025 and is projected to grow to USD 1.19 billion in 2026, with a CAGR of 7.45%, reaching USD 1.82 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 1.10 billion
Estimated Year [2026]	USD 1.19 billion
Forecast Year [2032]	USD 1.82 billion
CAGR (%)	7.45%

A strategic introduction to GalNAc-siRNA conjugates clarifying scientific rationale, translational progress, and the foundational implications for therapeutic development

GalNAc-conjugated small interfering RNA therapeutics represent a decisive inflection point in the development of targeted gene silencing medicines, combining receptor-mediated hepatic delivery with potent, sequence-specific knockdown. The convergence of chemistry, delivery engineering, and improved duplex design has repositioned RNA interference from a laboratory phenomenon to a viable therapeutic modality for liver-centric indications. As academic discoveries matured into clinical-stage assets, stakeholders across discovery, clinical development, manufacturing, and commercialization have adapted their capabilities to contend with the distinct requirements of oligonucleotide therapeutics.

This introduction frames the scientific rationale and translational trajectory that underpin the GalNAc-siRNA field, clarifying how improvements in stability, reduced off-target effects, and predictable pharmacokinetics have driven a renewed interest among development-stage companies and established biopharmaceutical players. Furthermore, regulatory pathways and clinical precedent have begun to crystallize, enabling more consistent development strategies. In light of these developments, decision-makers need concise, actionable intelligence that connects molecular design choices to clinical endpoints and downstream commercial considerations. The subsequent sections synthesize technological shifts, policy influences, segmentation dynamics, regional differentiation, and corporate activity to provide a cohesive baseline for strategy formation and stakeholder dialogue.

Critical transformative shifts in technology, regulatory precedents, and commercial strategies that are redefining the GalNAc-siRNA development and deployment landscape

The landscape for GalNAc-siRNA therapeutics has undergone transformative shifts driven by scientific refinements, regulatory normalization, and evolving commercial models. Advances in ligand-receptor targeting chemistry have improved hepatocyte uptake while limiting systemic exposure, which in turn has reduced safety uncertainties and shortened translational timelines. Simultaneously, developers emphasize optimization of duplex chemistry to enhance durability of effect and reduce dosing frequency, thereby improving patient adherence potential and payer receptivity.

Regulatory and clinical precedents have reduced perceived execution risk, prompting new entrants to form strategic alliances with contract development and manufacturing organizations to secure scalable production capacity. In parallel, investment flows have diversified, with capital moving toward platform-enabled companies that demonstrate reproducible delivery and modular development pathways across multiple indications. Commercial models have also shifted: instead of one-off product launches, organizations are exploring portfolio-based approaches that leverage shared delivery platforms and centralized hepatic expertise. These dynamics collectively elevate the importance of integrated strategies that reconcile scientific differentiation with pragmatic commercialization planning, including pricing structures tied to clinical durability and real-world performance.

How United States tariff adjustments for 2025 will affect procurement, manufacturing localization, and supply chain resilience strategies for GalNAc-siRNA developers

The imposition of United States tariffs and trade measures announced for 2025 introduces a material variable for supply chain planning, procurement, and manufacturing economics within the GalNAc-siRNA ecosystem. Although therapeutics and active pharmaceutical ingredients often benefit from specialized trade classifications and negotiated exemptions, changes in tariff schedules influence the landed cost of reagents, raw materials, and specialized instrumentation that support oligonucleotide synthesis. Consequently, organizations must revisit sourcing strategies and supplier agreements to mitigate input cost volatility while preserving quality and regulatory compliance.

In response, many developers are reassessing localization of critical manufacturing steps and expanding qualified supplier networks across multiple jurisdictions to reduce exposure to single-country supply disruptions. Contract manufacturing partners are adapting by refining cost models, optimizing inventory buffers, and investing in modular capacity that can be shifted geographically. Additionally, procurement teams are increasingly incorporating tariff scenarios into supplier selection matrices and total cost of ownership analyses to ensure that commercial pricing, reimbursement discussions, and contract negotiations reflect realistic cost structures. Ultimately, a disciplined approach to supply chain resilience-encompassing dual sourcing, regional redundancy, and early supplier qualification-will prove essential for organizations operating in this evolving trade environment.

Deep segmentation insights explaining how therapeutic indications, care settings, distribution channels, patient age groups, and application types drive differentiated development and commercialization approaches

Segmentation insights reveal that therapeutic focus, end-user settings, distribution pathways, patient demographics, and application types each impose unique requirements on development and commercialization strategies. When considering indication, the field spans metabolic disorders, oncology, and rare diseases, with metabolic disorders subdivided to address hypercholesterolemia and type 2 diabetes, oncology concentrating on liver cancer, and rare diseases encompassing hereditary transthyretin amyloidosis and hemophilia A. These clinical targets dictate differing clinical trial designs, safety monitoring frameworks, and long-term outcome measures, requiring program teams to align preclinical models with indication-specific endpoints.

From an end-user perspective, delivery models must accommodate home healthcare administration, hospital-based infusion or outpatient dosing, research institute collaborations for early-stage trials, and specialty clinic management for chronic administration. Distribution channel differentiation across hospital pharmacies, online pharmacies, and retail pharmacies informs packaging, cold chain considerations, and patient support programs. Patient age group segmentation-split between adults and pediatric populations-further influences dosing strategies, safety margins, and caregiver engagement. Finally, application type separated into prophylaxis and treatment frames the value proposition, determining clinical trial duration, regulatory evidence expectations, and payer negotiation approaches. Integrating these segmentation dimensions into program strategy enables tailored development pathways that better reflect the clinical, operational, and commercial realities of each targeted use case.

Key regional insights into how Americas, Europe Middle East & Africa, and Asia-Pacific dynamics shape clinical development, manufacturing strategy, and market access pathways

Regional dynamics continuously shape clinical trial design, regulatory engagement, manufacturing footprint, and commercial roll-out plans for GalNAc-siRNA therapeutics. In the Americas, robust clinical trial infrastructure and a mature reimbursement environment create opportunities for accelerated trial enrollment and early commercial uptake, but also present intense payer scrutiny and elevated expectations for real-world evidence. Conversely, Europe, Middle East & Africa involves a mosaic of regulatory frameworks and market access pathways that require harmonized evidence packages and localized health economic models to maximize adoption across divergent national systems.

Asia-Pacific exhibits varied capabilities: certain markets offer rapid recruitment and cost-efficient manufacturing capacity, while others emphasize regulatory harmonization and expanded public health initiatives that can support broader access. These regional distinctions influence choices about where to site pivotal trials, how to structure manufacturing redundancy, and which market access value dossiers to prioritize. Consequently, strategic planning must account for differential clinical pathways, regional reimbursement sensitivities, intellectual property environments, and local partner selection criteria to ensure effective deployment across multiple geographies.

Key company insights revealing how platform differentiation, strategic partnerships, and intellectual property approaches are shaping competitive dynamics and deal structures

Competitive and collaborative behaviors among firms active in the GalNAc-siRNA space reveal a dual focus on platform differentiation and pragmatic partnerships. Leading developers emphasize robust delivery chemistry, validated hepatic targeting, and scalable manufacturing processes, while smaller innovators pursue niche indications or novel chemistries to demonstrate proof of concept. Across the ecosystem, alliances with contract development and manufacturing organizations, strategic licensing agreements, and cross-disciplinary research collaborations have accelerated the translation of preclinical findings into clinical-stage programs.

Moreover, intellectual property strategies center on delivery frameworks, sequence optimization, and manufacturing processes, prompting many organizations to pursue a balanced approach that combines defensive patenting with selective cross-licensing. Financial and operational partnerships often take the form of co-development agreements, milestone-linked licenses, and manufacturing capacity guarantees, which serve to distribute development risk and align incentives. Investors and corporate development teams are increasingly assessing partners based on platform robustness, regulatory experience, and supply chain resilience rather than short-term asset valuations, which reshapes how deals are structured and how projects progress from bench to bedside.

Actionable recommendations for industry leaders to align platform development, supply chain resilience, evidence generation, and commercial models for durable competitive advantage

Leaders in therapeutic development and commercialization should adopt a set of targeted actions to translate scientific promise into durable market positions. First, integrate delivery platform choices with indication prioritization early in program design so that trial endpoints, manufacturing plans, and payer evidence strategies align seamlessly. Second, secure manufacturing and supply chain resilience through multi-jurisdictional qualifications and strategic partnerships with contract manufacturing organizations that can scale oligonucleotide production while meeting regulatory quality expectations.

Third, pursue value-focused evidence generation that emphasizes durability of effect, safety profile clarity, and real-world outcomes to strengthen reimbursement discussions. Fourth, structure commercial models to reflect differentiated distribution needs across hospital pharmacies, online channels, and retail outlets while ensuring consistent patient support and adherence infrastructure for adult and pediatric populations. Finally, maintain flexible business development approaches that combine defensive intellectual property with collaborative licensing and co-development arrangements to accelerate access and broaden therapeutic reach. Implementing these actions will tighten the link between translational innovation and sustainable commercial execution.

A transparent and reproducible research methodology combining primary stakeholder engagement, secondary literature synthesis, and cross-validated analytical techniques for reliable decision support

This research synthesizes primary and secondary intelligence to produce a rigorous, transparent methodology designed for reproducibility and decision relevance. Primary insights derive from structured interviews with industry executives, clinical investigators, regulatory specialists, manufacturing experts, and payers, complemented by anonymized case studies from development programs to capture practical challenges and mitigation strategies. Secondary analysis incorporates peer-reviewed literature, regulatory guidance, clinical trial registries, manufacturing best practices, and patent landscapes to triangulate findings and validate thematic trends.

Analytical techniques emphasize qualitative synthesis with scenario testing and sensitivity analysis for supply chain and regulatory contingencies. Evidence was cross-validated through multiple stakeholder perspectives to minimize bias, and key assumptions were documented to preserve traceability. Where appropriate, methodological notes highlight inclusion criteria for clinical programs and manufacturing technologies, and validation checkpoints ensure that recommendations reflect current operational realities. This structured approach supports actionable conclusions while maintaining methodological openness for further inquiry and update.

A concise conclusion synthesizing technological progress, regulatory realities, and strategic imperatives to advance GalNAc-siRNA programs from development to durable commercialization

In conclusion, GalNAc-siRNA conjugates stand at the intersection of compelling scientific progress and practical commercialization challenges, with delivery chemistry advances and regulatory clarity creating pathways for meaningful therapeutic impact. The maturation of platform capabilities has fostered new competitive dynamics characterized by platform differentiation, strategic partnerships, and concentrated efforts to secure manufacturing resilience. At the same time, external forces such as trade policy shifts and regional heterogeneity in regulatory and reimbursement systems necessitate adaptive strategies that balance global ambition with local execution.

Taken together, these dynamics underscore the need for integrated planning that connects early-stage design choices to clinical evidence generation, supply chain architecture, and commercial model design. For stakeholders aiming to lead within this evolving field, the imperative is to translate technical advantages into repeatable, scalable programs that meet clinical, regulatory, and economic demands. With disciplined implementation of the insights and recommendations herein, organizations can better position their programs to deliver therapeutic value and achieve sustainable operational trajectories.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. GalNAc-siRNA Conjugates Drug Market, by Indication

• 8.1. Metabolic Disorders
  • 8.1.1. Hypercholesterolemia
  • 8.1.2. Type 2 Diabetes
• 8.2. Oncology
• 8.3. Rare Diseases
  • 8.3.1. Hattr Amyloidosis
  • 8.3.2. Hemophilia A

9. GalNAc-siRNA Conjugates Drug Market, by Patient Age Group

• 9.1. Adults
• 9.2. Pediatric

10. GalNAc-siRNA Conjugates Drug Market, by Application Type

• 10.1. Prophylaxis
• 10.2. Treatment

11. GalNAc-siRNA Conjugates Drug Market, by End User

• 11.1. Home Healthcare
• 11.2. Hospitals
• 11.3. Research Institutes
• 11.4. Specialty Clinics

12. GalNAc-siRNA Conjugates Drug Market, by Distribution Channel

• 12.1. Hospital Pharmacies
• 12.2. Online Pharmacies
• 12.3. Retail Pharmacies

13. GalNAc-siRNA Conjugates Drug Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. GalNAc-siRNA Conjugates Drug Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. GalNAc-siRNA Conjugates Drug Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. United States GalNAc-siRNA Conjugates Drug Market

17. China GalNAc-siRNA Conjugates Drug Market

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025
• 18.5. Akcea Therapeutics, Inc.
• 18.6. Alnylam Pharmaceuticals, Inc.
• 18.7. Arrowhead Pharmaceuticals, Inc.
• 18.8. AstraZeneca plc
• 18.9. BioNTech SE
• 18.10. CureVac N.V.
• 18.11. Dicerna Pharmaceuticals, Inc.
• 18.12. GlaxoSmithKline plc
• 18.13. Ionis Pharmaceuticals, Inc.
• 18.14. Moderna, Inc.
• 18.15. Novartis AG
• 18.16. Novo Nordisk A/S
• 18.17. Pfizer Inc.
• 18.18. Roche Holding AG
• 18.19. Sanofi S.A.
• 18.20. Sarepta Therapeutics, Inc.
• 18.21. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

• FIGURE 1. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 12. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 13. CHINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY REGION, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HATTR AMYLOIDOSIS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HATTR AMYLOIDOSIS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HATTR AMYLOIDOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HEMOPHILIA A, BY REGION, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HEMOPHILIA A, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HEMOPHILIA A, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY TREATMENT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 50. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 51. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 52. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 53. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 54. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 55. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 56. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 57. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 58. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 59. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 60. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 61. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 62. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 63. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 64. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 65. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 66. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
• TABLE 67. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
• TABLE 68. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 69. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
• TABLE 70. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 71. AMERICAS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 72. NORTH AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 73. NORTH AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 74. NORTH AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
• TABLE 75. NORTH AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
• TABLE 76. NORTH AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 77. NORTH AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
• TABLE 78. NORTH AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 79. NORTH AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 80. LATIN AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 81. LATIN AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 82. LATIN AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
• TABLE 83. LATIN AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
• TABLE 84. LATIN AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 85. LATIN AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
• TABLE 86. LATIN AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 87. LATIN AMERICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 88. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 89. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 90. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
• TABLE 91. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
• TABLE 92. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 93. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
• TABLE 94. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 95. EUROPE, MIDDLE EAST & AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 96. EUROPE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 97. EUROPE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 98. EUROPE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
• TABLE 99. EUROPE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
• TABLE 100. EUROPE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 101. EUROPE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
• TABLE 102. EUROPE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 103. EUROPE GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 104. MIDDLE EAST GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 105. MIDDLE EAST GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 106. MIDDLE EAST GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
• TABLE 107. MIDDLE EAST GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
• TABLE 108. MIDDLE EAST GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 109. MIDDLE EAST GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
• TABLE 110. MIDDLE EAST GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 111. MIDDLE EAST GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 112. AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 113. AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 114. AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
• TABLE 115. AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
• TABLE 116. AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 117. AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
• TABLE 118. AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 119. AFRICA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 120. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 121. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 122. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
• TABLE 123. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
• TABLE 124. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 125. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
• TABLE 126. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 127. ASIA-PACIFIC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 128. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 129. ASEAN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 130. ASEAN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 131. ASEAN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
• TABLE 132. ASEAN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
• TABLE 133. ASEAN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 134. ASEAN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
• TABLE 135. ASEAN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 136. ASEAN GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 137. GCC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 138. GCC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 139. GCC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
• TABLE 140. GCC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
• TABLE 141. GCC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 142. GCC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
• TABLE 143. GCC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 144. GCC GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 145. EUROPEAN UNION GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 146. EUROPEAN UNION GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 147. EUROPEAN UNION GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
• TABLE 148. EUROPEAN UNION GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
• TABLE 149. EUROPEAN UNION GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 150. EUROPEAN UNION GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
• TABLE 151. EUROPEAN UNION GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 152. EUROPEAN UNION GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 153. BRICS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 154. BRICS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 155. BRICS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
• TABLE 156. BRICS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
• TABLE 157. BRICS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 158. BRICS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
• TABLE 159. BRICS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 160. BRICS GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 161. G7 GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 162. G7 GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 163. G7 GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
• TABLE 164. G7 GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
• TABLE 165. G7 GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 166. G7 GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
• TABLE 167. G7 GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 168. G7 GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 169. NATO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 170. NATO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 171. NATO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
• TABLE 172. NATO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
• TABLE 173. NATO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 174. NATO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
• TABLE 175. NATO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 176. NATO GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 177. GLOBAL GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 178. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 179. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 180. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
• TABLE 181. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
• TABLE 182. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 183. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
• TABLE 184. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 185. UNITED STATES GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 186. CHINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 187. CHINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 188. CHINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
• TABLE 189. CHINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
• TABLE 190. CHINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 191. CHINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
• TABLE 192. CHINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 193. CHINA GALNAC-SIRNA CONJUGATES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)